Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574378 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL21777886 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL21777884 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL1574380 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL3875618 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL25430032 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL22283970 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL19520745 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL23091621 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL15900199 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999745-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20240132520-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
| WO-2023229378-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4263536-A1 | PHARMACEUTICAL COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4249489-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-09-27 | — | — | EP | disclosed |
| EP-3193600-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016191524-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160222056-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2016040505-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | CHRM2 4847/4885CHRM1 4830/4885CHRM3 4788/4885 |
| US-11999745-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM3 4/4885 |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | CHRM2 2/4885CHRM1 4/4885CHRM3 5/4885 |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | ALPI, TPMT, SLC10A2 | CHRM2 1279/4885CHRM1 934/4885CHRM3 1203/4885 |
| US-20160222056-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | CHRM2 2642/4885CHRM1 2442/4885CHRM3 2119/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | CHRM2 4760/4885CHRM1 4390/4885CHRM3 4461/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CHRM2 4766/4885CHRM1 4786/4885CHRM3 4834/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | CHRM2 638/4885CHRM1 525/4885CHRM3 256/4885 |
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | DGKA, DGKB, DGKK | CHRM2 3989/4885CHRM1 2788/4885CHRM3 3520/4885 |
| US-20240132520-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | CHRM2 4847/4885CHRM1 4830/4885CHRM3 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.